EDIT Share Price Performance
US$2.37
1.03 (76.21%)
Price US$2.37
Share Pricen/a
Analysts Are Upgrading Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
Nov 13
Editas Medicine, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 29 Fair Values set on narratives written by author
EDIT Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Editas Medicine, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -2.05
- -139.66%
- -430.84%
- 0%
About EDIT
- Founded
- 2013
- Employees
- 246
- CEO
- WebsiteView website
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
